chlorpheniramine maleate; codeine phosphate · Mainpointe · NDA 206323
Tuxarin Er
Earliest generic entry, as listed
3 Jan 2032
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 9066942, US 9107921.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9066942 | use U-1716 | 3 Jan 2032 |
| US 9107921 | product | 3 Jan 2032 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206323 · 001 | tablet, extended release, oral | 8MG;54.3MG | 3 Jan 2032 |